SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue declined to Rs. 50962.10 millions for the quarter ended September 2023 as compared to Rs. 52852.90 millions during the corresponding quarter last year.Net profit declined -26.74% to Rs. 8886.30 millions from Rs. 12130.10 millions.A decline of 14928.60 millions was observed in the OP in the quarter ended September 2023 from 17048.80 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 50962.10 52852.90 -3.58 95622.80 102181.70 -6.42 208121.40 155859.80 33.53
Other Income 1159.30 417.10 177.94 2794.70 2179.20 28.24 3292.90 11968.80 -72.49
PBIDT 14928.60 17048.80 -12.44 26051.60 32035.30 -18.68 67518.90 38654.40 74.67
Interest 1936.30 927.70 108.72 3515.70 1798.40 95.49 4721.80 3881.00 21.66
PBDT 12992.30 16121.10 -19.41 21043.80 30236.90 -30.40 33419.20 16568.10 101.71
Depreciation 3927.10 3839.50 2.28 8079.80 7584.50 6.53 16008.70 13499.50 18.59
PBT 9065.20 12281.60 -26.19 12964.00 22652.40 -42.77 17410.50 3068.60 467.38
TAX 178.90 151.50 18.09 271.30 404.30 -32.90 503.30 4068.50 -87.63
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 8886.30 12130.10 -26.74 12692.70 22248.10 -42.95 16907.20 -999.90 -1790.89
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 29.29 32.26 -9.19 27.24 31.35 -13.10 32.44 24.80 30.81

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×